title: Refractive, topographic, tomographic, and aberrometric analysis of keratoconic eyes undergoing corneal cross-linking.
abstract: OBJECTIVE
  To report refractive, topographic, tomographic, and aberrometric outcomes 12 months after corneal cross-linking (CXL) in eyes with progressive advanced keratoconus.
  
  
  METHODS
  Prospective, nonrandomized, single-center clinical study.
  
  
  METHODS
  Twenty-eight eyes undergoing CXL between April and June 2006.
  
  
  METHODS
  Riboflavin-ultraviolet A (UVA)-induced CXL included instillation of 0.1% riboflavin-20% dextrane solution 30 minutes before UVA irradiation and every 5 minutes for an additional 30 minutes during irradiation.
  
  
  METHODS
  Uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), sphere and cylinder refraction, topography, tomography, aberrometry, and endothelial cell count were evaluated at baseline and at 1, 3, 6, and 12 months follow-up.
  
  
  RESULTS
  Mean baseline UCVA and BSCVA were 0.17+/-0.09 and 0.52+/-0.17, respectively; 12-month mean UCVA and BSCVA were 0.27+/-0.08 and 0.72+/-0.16, a statistically significant difference (P<0.05). Mean spherical equivalent refraction showed a significant decrease of 0.41 diopters (D). Mean baseline simulated keratometry (SIM K) flattest and steepest meridians and SIM K average were 46.10, 50.37, and 48.08 D, respectively; at 12 months, 40.22, 44.21, and 42.01 D, respectively, were recorded, a difference that was significant for all 3 indices (P<0.05). Mean average pupillary power (APP) changed significantly from 47.50 to 41.04 D at 12 months (P<0.05) and apical keratometry (AK) from 58.94 to 55.18 D (P<0.05). The treated eyes showed no deterioration of the Klyce indices at 6 months postoperatively, whereas the untreated (contralateral) eyes did show deterioration. For a 3-mm pupil, there was a significant reduction (P<0.05) in whole eye (total), corneal, higher order, and astigmatic wavefront aberrations. A significant difference (P<0.05) in total coma and total spherical aberration after CXL was also observed. Mean baseline pupil center pachymetry and total corneal volume decreased significantly (P<0.05) to 470.09+/-29.01 microm and 57.17+/-3.21 mm(3) from baseline values of 490.68+/-30.69 microm and 59.37+/-4.36 mm(3), respectively. Endothelial cell counts did not changed significantly (P=0.13).
  
  
  CONCLUSIONS
  Corneal cross-linking seems to be effective in improving UCVA and BSCVA in eyes with progressive keratoconus by significantly reducing corneal APP, AK, and corneal and total wavefront aberrations at 1 year postoperatively.
authors.affiliation: Department Ophthalmology, Istituto Clinico Humanitas, Rozzano, Milan, Italy. info@vincieye.it
authors.forename: Paolo
authors.initials: P
authors.lastname: Vinciguerra
authors.forename: Elena
authors.initials: E
authors.lastname: Albè
authors.forename: Silvia
authors.initials: S
authors.lastname: Trazza
authors.forename: Pietro
authors.initials: P
authors.lastname: Rosetta
authors.forename: Riccardo
authors.initials: R
authors.lastname: Vinciguerra
authors.forename: Theo
authors.initials: T
authors.lastname: Seiler
authors.forename: Dan
authors.initials: D
authors.lastname: Epstein
mesh_terms: D000328:Adult; D002452:Cell Count; D003094:Collagen / Q000378:metabolism*; D003315:Cornea / Q000378:metabolism* / Q000503:physiopathology; D019781:Corneal Topography; D004728:Endothelium, Corneal / Q000473:pathology; D005260:Female; D006801:Humans; D007640:Keratoconus / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011446:Prospective Studies; D012029:Refraction, Ocular / Q000502:physiology*; D012030:Refractive Errors / Q000503:physiopathology; D012256:Riboflavin / Q000627:therapeutic use*; D014466:Ultraviolet Rays; D014792:Visual Acuity / Q000502:physiology
chemical_list: D017319:Photosensitizing Agents; D003094:Collagen; D012256:Riboflavin